Literature DB >> 26170259

PI3K pathway inhibition in GBM—is there a signal?

Donna Nichol1, Ingo K Mellinghoff1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26170259      PMCID: PMC4588764          DOI: 10.1093/neuonc/nov124

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  17 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

3.  Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.

Authors:  Zhoulei Li; Ken Herrmann; Sabine Pirsig; Kathrin Philipp-Abbrederis; Martin Henninger; Michaela Aichler; Annette Feuchtinger; Axel Walch; Ambros J Beer; Ingo Ringshausen; Kelsey L Pomykala; Klemens Scheidhauer; Markus Schwaiger; Ulrich Keller; Andreas K Buck
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

4.  mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Authors:  Moshe Elkabets; Sadhna Vora; Dejan Juric; Natasha Morse; Mari Mino-Kenudson; Taru Muranen; Jessica Tao; Ana Bosch Campos; Jordi Rodon; Yasir H Ibrahim; Violeta Serra; Vanessa Rodrik-Outmezguine; Saswati Hazra; Sharat Singh; Phillip Kim; Cornelia Quadt; Manway Liu; Alan Huang; Neal Rosen; Jeffrey A Engelman; Maurizio Scaltriti; José Baselga
Journal:  Sci Transl Med       Date:  2013-07-31       Impact factor: 17.956

Review 5.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

6.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Authors:  Dimpy Koul; Ruijun Shen; Yong-Wan Kim; Yasuko Kondo; Yiling Lu; Jim Bankson; Sabrina M Ronen; D Lynn Kirkpatrick; Garth Powis; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2010-02-15       Impact factor: 12.300

Review 7.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

Authors:  Samuel J Klempner; Andrea P Myers; Lewis C Cantley
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

8.  Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors:  Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

10.  [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.

Authors:  Christopher Cawthorne; Natalie Burrows; Roben G Gieling; Christopher J Morrow; Duncan Forster; Jamil Gregory; Marc Radigois; Alison Smigova; Muhammad Babur; Kathryn Simpson; Cassandra Hodgkinson; Gavin Brown; Adam McMahon; Caroline Dive; Duncan Hiscock; Ian Wilson; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

View more
  5 in total

1.  MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.

Authors:  Haiqian Liang; Renjie Wang; Ying Jin; Jianwei Li; Sai Zhang
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

2.  Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma.

Authors:  Benjamin M Ellingson; Jingwen Yao; Catalina Raymond; David A Nathanson; Ararat Chakhoyan; Jeremy Simpson; James S Garner; Alan G Olivero; Lars U Mueller; Jordi Rodon; Elizabeth Gerstner; Timothy F Cloughesy; Patrick Y Wen
Journal:  Clin Cancer Res       Date:  2020-04-08       Impact factor: 12.531

3.  Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Authors:  Malak Abedalthagafi; Wenya Linda Bi; Ayal A Aizer; Parker H Merrill; Ryan Brewster; Pankaj K Agarwalla; Marc L Listewnik; Dora Dias-Santagata; Aaron R Thorner; Paul Van Hummelen; Priscilla K Brastianos; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Shakti H Ramkissoon; Rebecca D Folkerth; Keith L Ligon; Azra H Ligon; Brian M Alexander; Ian F Dunn; Rameen Beroukhim; Sandro Santagata
Journal:  Neuro Oncol       Date:  2016-01-28       Impact factor: 12.300

Review 4.  Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review.

Authors:  Ying Zhang; Pan Guo; Zhe Ma; Peng Lu; Dereje Kebebe; Zhidong Liu
Journal:  J Nanobiotechnology       Date:  2021-08-23       Impact factor: 10.435

5.  A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma.

Authors:  Nicholas J Eustace; Joshua C Anderson; Jason M Warram; Hayley N Widden; Rune T Pedersen; Hasan Alrefai; Zeel Patel; Patricia H Hicks; William J Placzek; G Yancey Gillespie; Anita B Hjelmeland; Christopher D Willey
Journal:  Oncogene       Date:  2020-10-19       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.